Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
暂无分享,去创建一个
G. Montepiedra | T. Sterling | G. Theron | T. Chipato | L. Stranix-Chibanda | Amita Gupta | A. Weinberg | N. Chakhtoura | G. Masheto | Tichaona Vhembo | V. Kulkarni | Sarah Bradford | L. Aaron | A. Shayo | Enid Kabugho | D. Costello | M. Mutambanengwe | V. Chanaiwa | Priya Singh | Patrick Jean-Phillippe | A. Golner | Mpho Raesi
[1] G. Montepiedra,et al. Coordination of inflammatory responses in children with perinatally acquired HIV infection , 2022, AIDS.
[2] M. Hughes,et al. High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis , 2022, The Pediatric infectious disease journal.
[3] T. Sterling,et al. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil , 2021, Microbiology spectrum.
[4] R. Chaisson,et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis , 2021, The Lancet. Infectious diseases.
[5] Brian G. Williams,et al. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. , 2021, The lancet. HIV.
[6] G. Montepiedra,et al. Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] B. Richardson,et al. A randomized controlled trial of isoniazid to prevent Mycobacterium tuberculosis infection in Kenyan HIV-exposed uninfected infants. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] Kaylynn Aiona,et al. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System , 2020, The Pediatric infectious disease journal.
[9] H. Zar,et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis , 2020, The Lancet.
[10] L. Myer,et al. Safety and Effectiveness of Isoniazid Preventive Therapy in HIV-Positive Pregnant Women on Art: An Observational Study using Linked Population Data. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] A. Harries,et al. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe , 2019, PloS one.
[12] G. Montepiedra,et al. Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. , 2019, The New England journal of medicine.
[13] Degefaye Zelalem Anlay,et al. Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study , 2019, BMC Infectious Diseases.
[14] R. Chaisson,et al. Building a tuberculosis-free world: The Lancet Commission on tuberculosis , 2019, The Lancet.
[15] M. Hatherill,et al. Diagnostic Accuracy of Early Secretory Antigenic Target-6–Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] G. Alter,et al. Sex differences in vaccine-induced humoral immunity , 2018, Seminars in Immunopathology.
[17] A. Mandalakas,et al. High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial , 2018, The Pediatric infectious disease journal.
[18] H. Zar,et al. Tuberculin skin test conversion and primary progressive tuberculosis disease in the first 5 years of life: a birth cohort study from Cape Town, South Africa , 2018, The Lancet. Child & adolescent health.
[19] Helen E Jenkins,et al. The global burden of tuberculosis mortality in children: a mathematical modelling study , 2017, The Lancet. Global health.
[20] J. Andrews,et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. , 2017, The Lancet. Respiratory medicine.
[21] B. Kampmann,et al. The impact of BCG vaccination on tuberculin skin test responses in children is age dependent: evidence to be considered when screening children for tuberculosis infection , 2016, Thorax.
[22] D. Havlir,et al. Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda , 2016, The Pediatric infectious disease journal.
[23] Marco Schito,et al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] E. Chiappini,et al. Interferon-Gamma Release Assay Sensitivity in Children Younger Than 5 Years is Insufficient to Replace the Use of Tuberculin Skin Test in Western Countries , 2014, The Pediatric infectious disease journal.
[25] A. Benedetti,et al. Reproducibility of interferon gamma (IFN-γ) release Assays. A systematic review. , 2014, Annals of the American Thoracic Society.
[26] S. Esposito,et al. Performance of interferon-&ggr; Release Assay for the Diagnosis of Active or Latent Tuberculosis in Children in the First 2 Years of Age: A Multicenter Study of the Italian Society of Pediatric Infectious Diseases , 2014, The Pediatric infectious disease journal.
[27] G. Maartens,et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.
[28] D. Shingadia,et al. Epidemiology and disease burden of tuberculosis in children: a global perspective , 2014, Infection and drug resistance.
[29] G. John-Stewart,et al. High Prevalence of Tuberculosis Infection in HIV-1 Exposed Kenyan Infants , 2014, The Pediatric infectious disease journal.
[30] M. Pai,et al. Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection , 2014, Clinical Microbiology Reviews.
[31] B. Marais,et al. Tuberculosis in children. , 2012, The New England journal of medicine.
[32] Amita Gupta,et al. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] C. Wiysonge,et al. The Utility of an Interferon Gamma Release Assay for Diagnosis of Latent Tuberculosis Infection and Disease in Children: A Systematic Review and Meta-analysis , 2011, The Pediatric infectious disease journal.
[34] P. Aaby,et al. Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau , 2010, Thorax.
[35] K. Castro,et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.